<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Stroke: percent of acute ischemic stroke patients for whom IV t-PA was initiated at the hospital within 3 hours (less than or equal to 180 minutes) of time last known well.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Specifications manual for national hospital inpatient quality measures, version 4.2b. Centers for Medicare &amp; Medicaid Services (CMS), The Joint Commission; 2013 Jan. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="MSH: Acute Disease ; Infusions, Intravenous ; Stroke ; Thrombolytic Therapy ; Time Factors ; Tissue Plasminogen Activator "/><FieldValue Value="MTH: Alteplase ; Cerebrovascular accident ; Intravenous infusion procedures ; Ischemic stroke "/><FieldValue Value="PDQ: recombinant tissue plasminogen activator ; thrombolytic therapy "/><FieldValue Value="SNOMEDCT_US: Acute disease ; Alteplase ; Cerebrovascular accident ; Intravenous infusion ; Ischemic stroke ; Thrombolytic therapy "/><FieldValue Value="UMD: Intravenous Administration Sets  (12-157)"/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure* is used to assess the percent of acute ischemic stroke patients 18 years of age and older who arrive at the hospital within 120 minutes (2 hours) of time last known well and for whom intravenous recombinant tissue plasminogen activator (IV r-TPA or t-PA) was initiated at the hospital within 180 minutes (3 hours) of time last known well.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*This is a Joint Commission only measure.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The administration of thrombolytic agents to carefully screened, eligible patients with acute ischemic stroke has been shown to be beneficial in several clinical trials. These included two positive randomized controlled trials in the United States (U.S.): the National Institute of Neurological Disorders and Stroke (NINDS) Studies, Part I and Part II. Based on the results of these studies, the U.S. Food and Drug Administration approved the use of intravenous recombinant tissue plasminogen activator (IV r-TPA or t-PA) for the treatment of acute ischemic stroke when given within 3 hours of stroke symptom onset. A large meta-analysis controlling for factors associated with stroke outcome confirmed the benefit of IV tPA in patients treated within 3 hours of symptom onset. While controversy still exists among some specialists, the major society practice guidelines developed in the U.S. all recommend the use of IV t-PA for eligible patients. Physicians with experience and skill in stroke management and the interpretation of computed tomography (CT) scans should supervise treatment.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005 Apr;36(4):916-23. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15800252&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM, American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology [trunc]. Stroke. 2007 May;38(5):1655-711. [738 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17431204&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):483S-512S. [202 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15383482&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brott TG, Clark WM, Fagan SC, Grotta JC, Hopkins LN, Jauch EC, Latchaw RE, Starkman S. Stroke: the first hours. Guidelines for acute treatment. Englewood (CO): National Stroke Association (NSA); 2000. 14 p.  [76 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr, American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009 Aug;40(8):2945-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19478221&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S, ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 6;363(9411):768-74. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15016487&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18815396&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute  hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995 Oct 4;274(13):1017-25. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7563451&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Institute for Clinical Systems Improvement (ICSI). Diagnosis and initial treatment of ischemic stroke. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2001 Oct. 60 p.  [110 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Management of patients with stroke. I: assessment, investigation, immediate management and secondary prevention. A national clinical guideline recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 1997 May. 27 p.&amp;nbsp;(SIGN publication; no. 13).&amp;nbsp; [46 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000 Dec 12;55(11):1649-55. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11113218&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke [trunc]. Stroke. 2006 Feb;37(2):577-617. [466 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16432246&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995 Dec 14;333(24):1581-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7477192&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Stroke; thrombolytic therapy; intravenous recombinant tissue plasminogen activator (IV r-TPA or t-PA)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute ischemic stroke patients whose time of arrival is within 2 hours (less than or equal to 120 minutes) of time last known well (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Acute ischemic stroke patients for whom intravenous (IV) thrombolytic therapy was initiated at the hospital within 3 hours (less than or equal to 180 minutes) of time last known well&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /><FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" /><FieldValue Value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stroke ranks as the number four cause of death in the United States, following diseases of the heart, cancer, and chronic lung-related diseases. Each year, &amp;asymp; 795,000 people experience a new or recurrent stroke. Approximately 610,000 of these are first attacks, and 185,000 are recurrent strokes. These numbers equate to one stroke victim every 40 seconds on average. According to 2008 mortality data, one of every 18 deaths in the United States is attributable to stroke. Women have a higher lifetime risk of stroke than men. Lifetime risk of stroke among those 55 to 75 years of age was 1 in 5 for women (20% to 21%) and approximately 1 in 6 for men (14% to 17%). Blacks have a risk of first-ever stroke that is almost twice that of whites (American Heart Association [AHA], 2012). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke is also a leading cause of long-term disability (Centers for Disease Control and Prevention [CDC], 2009). Data from the National Heart, Lung and Blood Institute (NHLBI) revealed that 50% of ischemic stroke survivors age greater than 65 years had some hemiparesis; 35% experienced depressive symptoms; 30% were unable to ambulate without assistance; 26% were dependent in activities of daily living; 19% had aphasia; and 26% were institutionalized in a nursing home. The mean lifetime cost of ischemic stroke, including inpatient care, rehabilitation, and follow-up as necessary for residual deficits are estimated at $140,048 per person (AHA, 2012). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thrombolytic therapy is one of the most promising treatments for acute ischemic stroke. The majority of strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with clot dissolving (thrombolytic) drugs can restore blood flow before major brain damage has occurred. In the United States (U.S.), Canada, and most European countries, alteplase/recombinant tissue plasminogen activator (rt-PA) has been approved for use within three hours of stroke symptom onset. Successful treatment is likely to improve neurological outcomes for ischemic stroke patients at three months and later; however, intracranial hemorrhage is a serious complication of therapy and may be fatal (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical practice guidelines for intravenous thrombolysis with rt-PA (Adams et al., 2007) cite the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study (1995), which partially supported the approval of rt-PA by the U.S. Food and Drug Administration (FDA). The NINDS trial was conducted in two consecutive parts. Part A trials in the 1980s studied very low doses of thrombolytic therapy, given daily by intravenous route for several days. The onset of treatment occurred anytime from 5 to 14 days post symptom onset. Part A trials did not collect data on functional outcome. Part B trials from the 1990s and later used a single large dose of thrombolytic drug (80 to 100 mg rt-PA), given intravenously (IV) or intra-arterially (IA) within three, six, nine, or 24 hours of stroke. The primary end point in Part B of the study was a favorable outcome, defined as complete or nearly complete neurological recovery 3 months after stroke. Favorable outcomes were achieved in 31% to 50% of patients treated with rt-PA, as compared to 20% to 38% of patients given placebo (Kwiatkowski et al., 1999). The benefit was similar one year after stoke. The major risk of treatment was symptomatic intracranial hemorrhage which occurred in 6.4% of patients treated with rt-PA and 0.6% of patients given placebo (Marler et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In 2008, European Cooperative Acute Stoke Study (ECASS)-3, a multi-center, prospective, randomized, placebo-controlled trial, studied the administration of rt-PA between three and 4.5 hours of stroke symptom onset (Hacke et al., 2008). The trial enrolled 418 patients treated with rt-PA per the current dosing guidelines (i.e., 0.9 mg/kg (maximum of 90 mg) with 10% given as an initial IV bolus and the remainder infused over one hour) and compared them with 403 who were given placebo. The frequency of the primary efficacy outcome (i.e., modified Rankin Scale score of 0 to 1 at 90 days after treatment) was significantly greater with rt-PA (52.4%) than with placebo (45.2%; odds ratio [OR] 1.34, 95% confidence interval [CI] 1.02 to 1.76; risk ratio 1.16, 95% CI 1.01 to 1.34; P=0.04). The point estimate for the degree of benefit seen in ECASS-3 (OR for global favorable outcome, 1.28, 95% CI 1.00 to 1.65) was less than the point estimate of benefit found in the pool of patients enrolled for 0 to 3 hours after stroke symptom onset in the NINDS study (OR 1.9, 95% CI 1.2 to 2.9). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Currently, researchers, along with the field, continue to debate the risk of intracerebral hemorrhage with IV rt-PA in certain patient populations; however, the benefit of improved functional outcomes, and potential improvements in quality of life outweighs the decision to with hold treatment of the ischemia (Saposnik et al., 2012). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although the expanded timeframe of 3 to 4.5 hours for thrombolytic therapy was found to be effective for ischemic stroke patients and without significant increase in hemorrhagic events, the debate remains as to the benefit of the extended time frame. A treatment target of 3 hours remains the accepted recommendation as studies have shown the potential opportunity for improved outcomes is greater with earlier treatment. Delays in evaluation and initiation of therapy for eligible patients with acute ischemic stroke should be avoided. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="3502" OrdBy="170" ID="576" Name="Evidence for Additional Information Supporting Need for the Measure" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM, American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology [trunc]. Stroke. 2007 May;38(5):1655-711. [738 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17431204&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Heart Association. Heart disease and stroke statistics - 2013 update. Dallas (TX): American Heart Association; 2012. e68-e75 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):421-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19407734&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstern LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999 Jun 10;340(23):1781-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10362821&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, Johnston SC, Investigators of the Registry of the Canadian Stroke Network (RCSN), Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012 May;43(5):1315-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22308252&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Emergency Department" /><FieldValue Value="Hospital Inpatient" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Single Health Care Delivery or Public Health Organizations" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Specified" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Age greater than or equal to 18 years&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Making Care Safer&lt;/li&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Getting Better" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /><FieldValue Value="Safety" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Discharges January 1 through December 31&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Patients associated with provider" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Clinical Condition" /><FieldValue Value="Institutionalization" /><FieldValue Value="Patient/Individual (Consumer) Characteristic" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Discharges with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Principal Diagnosis Code for ischemic stroke (as defined in the appendices of the original measure documentation) whose time of arrival is within 2 hours (less than or equal to 120 minutes) of time last known well&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients less than 18 years of age &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who have a Length of Stay (LOS) greater than 120 days &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients enrolled in clinical trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients admitted for &lt;em&gt;Elective Carotid Intervention&lt;/em&gt; (as defined in the Data Dictionary) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Time Last Known Well&lt;/em&gt; (as defined in the Data Dictionary) to arrival in the emergency department (ED) greater than 2 hours &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with a documented &lt;em&gt;Reason For Not Initiating IV Thrombolytic&lt;/em&gt; (as defined in the Data Dictionary) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Acute ischemic stroke patients for whom intravenous (IV) thrombolytic therapy was initiated at the hospital within 3 hours (less than or equal to 180 minutes) of time last known well&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;None&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Institutionalization" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Administrative clinical data" /><FieldValue Value="Electronic health/medical record" /><FieldValue Value="Paper medical record" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;STK-4: thrombolytic therapy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="National Hospital Inpatient Quality Measures" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Stroke" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="Centers for Medicare &amp; Medicaid Services/The Joint Commission - None" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="The Joint Commission - Health Care Accreditation Organization" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All external funding for measure development has been received and used in full compliance with The Joint Commission's Corporate Sponsorship policies, which are available upon written request to The Joint Commission.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The composition of the group that developed the measure is available at: &lt;a href=&quot;http://www.jointcommission.org/assets/1/6/Roster_STK_Maintenance_TAP_web_posting_Jul2012.pdf&quot; title=&quot;The Joint Commission Web site&quot;&gt;http://www.jointcommission.org/assets/1/6/Roster_STK_Maintenance_TAP_web_posting_Jul2012.pdf&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Expert panel members have made full disclosure of relevant financial and conflict of interest information in accordance with the Joint Commission's Conflict of Interest policies, copies of which are available upon written request to The Joint Commission.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="82" OrdBy="700" ID="626" Name="Endorser" Type="orglist"><FieldValue Value="National Quality Forum - None" /></Field><Field FieldID="3091" OrdBy="705" ID="696" Name="NQF Number" Type="plain-text"><FieldValue Value="not defined yet" /></Field><Field FieldID="3510" OrdBy="710" ID="627" Name="Date of Endorsement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;2014 Jan 6&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3083" OrdBy="720" ID="628" Name="Measure Initiative(s)" Type="picklist-many"><FieldValue Value="Hospital Inpatient Quality Reporting Program" /><FieldValue Value="Physician Quality Reporting System" /><FieldValue Value="Quality Check®" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2013 Jan" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is reviewed and updated by the developing organization every 6 months.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;2014 Jan&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Please note&lt;/strong&gt;: This measure has been updated. The National Quality Measures Clearinghouse is working to update this summary.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;STK-4: Thrombolytic Therapy,&quot; is published in &quot;Specifications Manual for National Hospital Inpatient Quality Measures.&quot; An update of this document is available from &lt;a href=&quot;http://www.jointcommission.org/specifications_manual_for_national_hospital_inpatient_quality_measures.aspx&quot; title=&quot;The Joint Commission Web site&quot;&gt;The Joint Commission Web site&lt;/a&gt;. Information is also available from the &lt;a href=&quot;http://www.qualitynet.org/dcs/ContentServer?c=Page&amp;amp;pagename=QnetPublic/Page/QnetTier2&amp;amp;cid=1141662756099&quot; title=&quot;QualityNet Web site&quot;&gt;QualityNet Web site&lt;/a&gt;. Check The Joint Commission Web site and QualityNet Web site regularly for the most recent version of the specifications manual and for the applicable dates of discharge.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Joint Commission originally submitted this NQMC measure summary to ECRI Institute on April 30, 2009. This NQMC summary was reviewed accordingly by ECRI Institute on September 9, 2009. The information was verified by the measure developer on November 9, 2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Joint Commission informed NQMC that this measure was updated on April 28, 2010 and provided an updated version of the NQMC summary. This NQMC summary was updated accordingly by ECRI Institute on September 3, 2010.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was retrofitted into the new template on May 18, 2011.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Joint Commission informed NQMC that this measure was updated on August 13, 2012 and provided an updated version of the NQMC summary. This NQMC summary was updated accordingly by ECRI Institute on December 17, 2012.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Joint Commission informed NQMC that this measure was updated again on August 28, 2013 and provided an updated version of the NQMC summary. This NQMC summary was updated accordingly by ECRI Institute on January 30, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Specifications Manual for National Hospital Inpatient Quality Measures [Version 4.2b, January, 2013] is the collaborative work of the Centers for Medicare &amp;amp; Medicaid Services and The Joint Commission. The Specifications Manual is periodically updated by the Centers for Medicare &amp;amp; Medicaid Services and The Joint Commission. Users of the Specifications Manual for National Hospital Inpatient Quality Measures should periodically verify that the most up-to-date version is being utilized.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Specifications manual for national hospital inpatient quality measures, version 4.2b. Centers for Medicare &amp; Medicaid Services (CMS), The Joint Commission; 2013 Jan. various p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
